Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome
Authors:
Open Access
- 15 February 1990
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 75 (4) , 1024-1030
Abstract
We have analyzed the long term outcome of 197 patients who were treated for grade II to IV acute graft-versus-host disease (GVHD) following histocompatible allogeneic bone marrow transplantation (BMT). Of 469 recipients of sibling donor allografts performed at our center between January, 1979 and October, 1987, 197 patients (42%) developed greater than or equal to grade II acute GVHD at a median of 38 days (range 9 to 98 days) post-BMT. After treatment with corticosteroids (n = 160) or other immunosuppressive therapies (n = 37), 72 patients (41% +/- 8%; 95% confidence interval [CI]) achieved complete and continuing resolution of acute GVHD after a median of 21 days of therapy. Sixty- one patients required additional immunosuppressive therapy with high dose methylprednisolone, antithymocyte globulin (ATG)/steroids, or other therapies because of refractory or progressive symptoms of acute GVHD. Seven of these 61 patients eventually obtained complete and continuing remission after 13 to 57 days (median 50) of secondary treatment. The overall rate of chronic GVHD was 70% +/- 16%; 95% CI following grade II to IV acute GVHD. Twenty-five of the 197 patients never developed chronic GVHD, resulting in a Kaplan-Meier projection of 30% +/- 8% (95% CI) cure of moderate/severe acute GVHD. Analysis of clinical features associated with complete response (CR) to acute GVHD therapy identified more favorable responses to therapy in patients without either liver or skin involvement, patients with acute lymphoblastic leukemia, and donor/recipient pairs other than male patients with female donors. Older recipient age was not associated with more resistance to GVHD treatment. CR to GVHD treatment was associated with significantly better 5-year survival: 51% +/- 14% versus 32% +/- 11% for patients with therapy resistant acute GVHD (P = .004). GVHD was a major contributing cause of death in 49 of the 90 patients who died and was often complicated by infection or interstitial pneumonitis. Control of acute GVHD through immunosuppressive therapy did not affect the risk of leukemic relapse after transplantation.Keywords
This publication has 16 references indexed in Scilit:
- CYCLOSPORINE AS AN ALTERNATIVE TO CYCLOPHOSPHAMIDE IN THE TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASETransplantation, 1986
- TREATMENT OF HUMAN ACUTE GRAFT-VERSUS-HOST DISEASE WITH ANTITHYMOCYTE GLOBULIN AND CYCLOSPORINE WITH OR WITHOUT METHYLPREDNISOLONETransplantation, 1985
- Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporineThe American Journal of Medicine, 1985
- Graft‐versus‐host disease prophylaxis with anti‐T‐cell monoclonal antibody OKT3, prednisone and methotrexate in allogeneic bone‐marrow transplantationBritish Journal of Haematology, 1985
- A histopathologic study of gastric and small intestinal graft-versus-host disease following allogeneic bone marrow transplantationHuman Pathology, 1985
- HIGH-DOSE METHYLPREDNISOLONE TREATMENT FOR ACUTE GRAFT-VERSUS-HOST DISEASE AFTER BONE MARROW TRANSPLANTATION IN ADULTSTransplantation, 1984
- High dose bolus methylprednisolone for the treatment of acute graft versus host diseaseAnnals of Hematology, 1983
- PRETREATMENT OF DONOR BONE MARROW WITH MONOCLONAL ANTIBODY OKT3 FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC HISTOCOMPATIBLE BONE-MARROW TRANSPLANTATIONThe Lancet, 1982
- A Randomized Study of the Prevention of Acute Graft-versus-Host DiseaseNew England Journal of Medicine, 1982
- Treatment of graft‐versus‐host disease in human allogeneic marrow graft recipients: A randomized trial comparing antithymocyte globulin and corticosteroidsAmerican Journal of Hematology, 1981